Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.49 USD
Change Today +0.02 / 1.36%
Volume 74.7K
APRI On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

apricus biosciences inc (APRI) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/15 - $2.75
52 Week Low
12/19/14 - $0.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

apricus biosciences inc (APRI) Related Bloomberg News

View More Bloomberg News

apricus biosciences inc (APRI) Related Businessweek News

No Related Businessweek News Found

apricus biosciences inc (APRI) Details

Apricus Biosciences, Inc. engages in developing and commercializing products and product candidates in the areas of urology and rheumatology in the United States, Canada, Europe, and internationally. The company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. Its marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The company’s products under development include second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and RayVa, which is in Phase IIa clinical trial for the treatment of Raynaud’s Phenomenon. It also plans to initiate a Phase IIb trial for fispemifene, a tissue-specific selective estrogen receptor modulator to treat secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men; and out-license Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

23 Employees
Last Reported Date: 03/16/15
Founded in 1987

apricus biosciences inc (APRI) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $453.6K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $11.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $1.3K
Compensation as of Fiscal Year 2014.

apricus biosciences inc (APRI) Key Developments

Apricus Biosciences, Inc. Enrolls First Patients in Phase 2b Clinical Trial for Fispemifene in Men with Symptomatic Secondary Hypogonadism

Apricus Biosciences, Inc. announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator ("SERM"), for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone. The study will evaluate the safety and tolerability of oral fispemifene, and will assess the effects of treatment on the sexual symptoms using Patient Reported Outcome (PRO) endpoints. The study will also assess relevant pharmacodynamic and pharmacokinetic parameters to evaluate the ability of fispemifene to endogenously increase the serum testosterone level.  The study will enroll at approximately 15 sites in the United States and the Company expects it to run through the end of the year with topline data expected in the first quarter of 2016.

Apricus Biosciences Launches Erectile Dysfunction Drug Vitaros in France by Laboratoires Majorelle

Apricus Biosciences announced that it has launched Vitaros in France by Laboratoires Majorelle, the company's distributing partner. Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction, is also marketed as Vytaros in Belgium and Virirec in Spain. Laboratoires Majorelle is waiting for the subsequent publication in France's Journal Officiel of the pricing and reimbursement of Vitaros by the Economic Committee of Healthcare Products (Comite Economique des Produits de Sante). This is the final step in the reimbursement process for a new medicine in France. Apricus had signed an exclusive license agreement with Laboratoires Majorelle in November 2013 to market Vitaros in France, Monaco and certain African countries.

Apricus Biosciences, Inc. Approves Amendment to Amended and Restated Articles of Incorporation

Apricus Biosciences, Inc. announced that at the Annual Meeting of Stockholders held on May 14, 2015 approved an amendment to the company's amended and restated articles of incorporation to increase the number of authorized shares of common stock from 75,000,000 shares to a total of 150,000,000 shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APRI:US $1.49 USD +0.02

APRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $85.09 USD -0.59
Endo International PLC $86.19 USD -1.44
GlaxoSmithKline PLC 1,375 GBp +46.00
Pfizer Inc $35.76 USD +0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation APRI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 44.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APRICUS BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at